Argenica Therapeutics, the WA based biotechnology company developing novel therapeutics to reduce brain tissue death after stroke and other acute neurological conditions, and Perron Institute will participate in the 2026 European Stroke Organisation Conference (ESOC) 6-8 May.
A leading forum for stroke research and clinical care, this conference in the Netherlands will bring together the global stroke community to share latest scientific developments and innovations.
Argenica Therapeutics is developing and commercialising a novel drug based on the pioneering work of Professor Bruno Meloni and Clinical Professor Neville Knuckey at The University of Western Australia (UWA) and the Perron Institute.
The drug ARG-007 has neuroprotective properties with the potential to offer protection to the brain following stroke and other acute central nervous system injuries.
Professor Graeme Hankey AO, Perron Institute Chair in Stroke Research at UWA, will present on final results of the Phase 2 SEANCON trial of ARG-007 in acute ischaemic stroke patients.
This trial confirmed that ARG-007’s strongest benefit was for more severe ischaemic stroke patients who have the greatest need for neuroprotection.
Argenica’s second contribution, a poster authored by Dr Davide Carone, Senior Medical Director at Brainomix, has been selected as a Best Poster Finalist, to be awarded at the conclusion of the conference.
Dr Liz Dallimore, Managing Director of Argenica, commented: “ESOC is one of the top tier global stroke conferences.
“Being selected for both oral and poster presentations is a strong indicator of the quality and impact of the Phase 2 SEANCON trial.
“Oral presentations are typically reserved for the highest-ranked abstracts, and being selected as a Best Poster Finalist is another notable distinction.
“This is a fantastic recognition of the hard work and encouraging outcomes achieved in our Phase 2 trial of ARG-007 in acute ischaemic stroke patients.”
Based on an Argenica Therapeutics ASX announcement